Share
47 Posts.
lightbulb Created with Sketch. 9
clock Created with Sketch. 03/12/17
14:46
Share
Originally posted by nickdany123
↑
Thank you for chiming in. I am not sure the explanation provided by management at the AGM holds water for the simple fact that they already struck a deal with Aspen Pharmacare to market the product in ANZ. I happen to live in the USA and have some familiarity with how pharma companies set drug prices around the world. I doubt setting the price for the US first will have any bearing on how the product is priced around the world. Every market is different. Even in the EU, each country is its own market. What makes the US such an attractive market for pharma companies, unlike in most other countries, is the lack of price control on ethical drugs. Had they begun commercializing the product a year or so ago, they would have exposed the drug to potential research studies about its efficacy. Favorable medical research papers on the drug would in turn raise awareness and positively influence the opinions of the medical profession.
Expand
Hey, Nick - Very good to get another perspective from the US.
(20min delay)